Fact based stock research
Mochida Pharmaceutical (TSE:4534)

JP3922800002

Mochida Pharmaceutical stock research in summary

mochida.co.jp


Mochida Pharmaceutical shares are less expensive than other comparable stocks. They are safely financed and are good value, but show below average growth. We recommend evaluating whether the future of the company Mochida Pharmaceutical is really as difficult as the low price of the stock suggests. If you believe that the future of the company is market-typical or even better, then this could be an argument for a share purchase.


Latest Obermatt Ranks


Value Rank 75
Growth Rank 40
Safety Rank 100
Combined Rank 93
Country Japan
Industry Pharmaceuticals
Index
Size class Large

June 4, 2021. Stock data may be delayed. Login to get the most recent research.

Add to Watchlist
Filter Similar Stocks
Similar Top 10

Google: Mochida Pharmaceutical

News

Videos

Wikipedia about Mochida Pharmaceutical

Management

Employee Satisfaction

Customer Satisfaction

Research History: Mochida Pharmaceutical

RESEARCH HISTORY 2018 2019 2020 2021
VALUE
VALUE n/a
n/a
80
75
GROWTH
GROWTH n/a
n/a
31
40
SAFETY
SAFETY n/a
n/a
100
100
COMBINED
COMBINED n/a
n/a
84
93

Last update of Combined Rank: 4-Jun-2021. Financial reporting date used for calculating ranks: 31-Mar-2021. Stock research history is based on the Obermatt Method. The higher the rank, the better Mochida Pharmaceutical is in the corresponding investment strategy.


Value Metrics in Detail

VALUE METRICS 2018 2019 2020 2021
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S) n/a
n/a
66
75
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E) n/a
n/a
51
67
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book) n/a
n/a
80
80
DIVIDEND YIELD
DIVIDEND YIELD n/a
n/a
74
71
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE n/a
n/a
80
75

Last update of Value Rank: 4-Jun-2021. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Mochida Pharmaceutical; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2018 2019 2020 2021
REVENUE GROWTH
REVENUE GROWTH n/a
n/a
30
25
PROFIT GROWTH
PROFIT GROWTH n/a
n/a
69
67
STOCK RETURNS
STOCK RETURNS n/a
n/a
30
58
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH n/a
n/a
31
40

Last update of Growth Rank: 31-Mar-2021. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Mochida Pharmaceutical.


Safety Metrics in Detail

SAFETY METRICS 2018 2019 2020 2021
LEVERAGE
LEVERAGE n/a
n/a
96
94
REFINANCING
REFINANCING n/a
n/a
71
73
LIQUIDITY
LIQUIDITY n/a
n/a
97
94
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY n/a
n/a
100
100

Last update of Safety Rank: 28-May-2021. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Mochida Pharmaceutical and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Mochida Pharmaceutical from June 4, 2021.


We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.

Get stock news now

Investing made easy